Stock·NYSE·Technology
Amphenol Corp. (APH)
- Market cap
- $195.67B
- P/E
- 40.75
- Dividend yield
- 0.63%
- Street target
- $100.00median of 19 analysts
- 52-week range
- $59.01 $89.93
The short version
Where APH stands today, in four lines, and what CleaRank Financial AI makes of it.
APH at a glance
Amphenol Corp. (APH): Buy, 72/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($75.05 and $82.24).
- Earnings APH beat estimates in 7 of its last 7 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $921.4M and bought $1.3M over the last 18 months.
- Valuation P/E of 40.7 against 35.1 for the Technology sector: broadly in line with peers (+16%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Amphenol Corp. (APH) Buy, with a model score of 72/100.
The largest boost comes from the analysts' outlook, where 17 of 19 analysts rate the stock a buy and the median target is 26.0% above the price. The largest drag is momentum, as the 14-day RSI of 39.0 sits in the bearish zone. Trend signals are mixed: the price is 3.50% below its 50-day average of $82.24 yet 5.75% above its 200-day average of $75.05. The price has climbed 24.62% over the past year.
Only on CleaRank
Figures we compute ourselves from APH's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $79.36 is 3.5% below the 50-day simple moving average of $82.24.Price above its 200-day average ›
The price is 5.7% above the 200-day simple moving average of $75.05.50-day average above the 200-day ›
The 50-day average ($82.24) is 9.6% above the 200-day average ($75.05), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 66% of its 52-week range, between $59.01 and $89.93.
APH share price
Pick a period: each tab shows how far APH has moved over it, to the last close.
Today's trading
Where APH sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 40.75 is 16.1% above the Technology median of 35.1.P/S below the sector median ›
The price-to-sales ratio of 6.93 is 8.9% below the sector median of 7.6.Profitable over the last 12 months ›
Net income over the last 12 months was $5.1B on revenue of $29.0B, a net margin of 17.7%.Beat estimates in most recent reports ›
APH beat the EPS estimate in 7 of its last 7 reports.Pays a dividend ›
The trailing dividend yield is 0.63%, or $0.5 a share a year.
Key statistics
The headline figures for APH.
As of October 17, 2026, APH trades at $79.36, with a market value of $195.67B, a P/E ratio of 40.75 and a dividend yield of 0.63%.
What the numbers say
CleaRank Financial AI's reading of APH's valuation, growth and risks.
Amphenol Corp. (APH) is priced at 40.75 times earnings, compared with a Technology sector median of 35.1. That places the P/E 16.1% above the median, and the P/E is broadly in line with peers. On sales, the P/S of 6.93 is 8.8% below the sector median P/S of 7.6.
In the latest year revenue grew 55.00%, 30.8 percentage points faster than the sector median of 24.2%. Margins stand at a net margin of 17.73% and an operating margin of 29.78%. It generates a return on equity of 38.12%, above the sector median of 13.4%. Debt-to-equity of 1.20 and a trailing dividend yield of 0.63% ($0.5 a share a year) round out the fundamentals.
APH's most recent available report in our data, from April 29, 2026, topped forecasts by 11.58%, with EPS of $1.06 versus an estimate of $0.95. The share price nonetheless slipped 0.75% in the first session that followed.
The record is a clean sweep: 7 beats in 7 reports, but beats have not guaranteed gains: the stock fell the next day after 1 of them. The largest of the earlier reactions came after the October 22, 2025 report, which beat the estimate by 16.25% while the stock rose 4.95%. Looking ahead, analysts expect EPS of $2.68 this fiscal year (growth of 60.7%) and $3.33 the year after (growth of 24.1%).
Normal swings for APH run at about 2.21% a day. Over the last 18 months, insider sales totalled $921.4M against $1.3M of purchases; planned sales and tax sales on vesting shares make selling a weaker signal than buying.
APH against the Technology sector
How APH compares with the median Technology stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (16% difference), suggesting fair market pricing relative to industry standards.
Return vs XLK: Since May 6, 2025, APH has gained 99.1% against a gain of 71.7% for XLK.
Performance against XLK
APH and the Technology sector fund over the same days.
Revenue and earnings
How much APH sells, and how much of it becomes profit.
Revenue growth: Revenue grew 51.7% in FY2025 to $23.1B, from $15.2B a year earlier.
Profit margin: The net margin was 18.6% in FY2025, up from 16.0% the year before.
Profitable: APH earned $4.3B in FY2025.
Earnings reality check
Did APH beat what analysts expected, and how did the stock react?
Earnings record: APH beat the analyst estimate in 7 of the last 7 quarters.
Market reaction: The stock fell in the first session after 1 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Apr 29, 2026after close | $0.95 | $1.06 | +11.58% | -0.75% | -6.68% |
| Jan 28, 2026after close | $0.94 | $0.97 | +3.19% | +2.48% | -10.93% |
| Oct 22, 2025after close | $0.80 | $0.93 | +16.25% | +4.95% | +8.39% |
| Jul 23, 2025after close | $0.67 | $0.81 | +20.90% | +3.72% | +4.75% |
| Apr 23, 2025after close | $0.52 | $0.63 | +21.15% | +6.86% | +8.15% |
| Jan 22, 2025after close | $0.50 | $0.55 | +10.00% | +0.91% | -10.87% |
| Oct 23, 2024after close | $0.45 | $0.50 | +11.11% | +1.94% | -0.16% |
Reports after April 29, 2026 are not yet in our data.
As of October 17, 2026, APH has beaten the analyst EPS estimate in 7 of its last 7 reported quarters and fell in the first trading session after 1 of those beats; its most recent report in our data, on April 29, 2026, came in 11.58% above the estimate and the stock moved -0.75% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 39.0, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 39.0 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of APH
The score, the reasoning behind it, and what could move the price next.
Amphenol Corp. (APH) trades between its two main moving averages. At $79.36, the price is 5.75% above its 200-day average of $75.05 but 3.50% below its 50-day average of $82.24. That 50-day average sits 9.59% above the 200-day one. Within the 52-week range, which runs from $59.01 up to $89.93, the stock currently stands at 66% of the way up.
On momentum, the 14-day RSI reads 39.0, in the bearish zone, above the oversold line, although the MACD line is positive, which pulls the other way. The price is up over each of these periods: 2.72% over the past month, 4.97% over the past three months and 24.62% over the past year.
Earnings beat ›
The April 29, 2026 report beat the EPS estimate by 11.58%, and the share price fell 0.75% in the first session after it.
Source: Earnings report, April 29, 2026Rating reaffirmed ›
Citigroup kept its Buy rating on October 8, 2026.
Source: Analyst action, Citigroup, October 8, 2026
New analyst coverage ›
Bernstein started coverage at Outperform on September 23, 2026.
Source: Analyst action, Bernstein, September 23, 2026
- The two closest levels to watch are the 50-day SMA at $82.24, which sits above the price, and the 200-day SMA at $75.05, which sits below it.
- The 14-day RSI reads 39.0, in the bearish zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- The share price declined 0.75% in the first session after the April 29, 2026 report, even though APH has beaten estimates in 7 of the last 7 reports.
APH is in a mixed trend: the price is above its 200-day average of $75.05 but below its 50-day average of $82.24. A close above the 50-day would flip both signals to up, while a close below the 200-day would flip both to down. For now the price sits between the 200-day SMA ($75.05) below and the 50-day SMA ($82.24) above.
With the RSI in the bearish band, momentum is not strong enough to suggest a quick rebound.
Technical indicators
Momentum and trend for APH, from its daily closes.
As of October 17, 2026, with APH at $79.36, its 14-day RSI is 39.0 (showing bearish momentum without being oversold), its 50-day simple moving average is $82.24 and its 200-day is $75.05.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What APH moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, APH's 1-year correlation of daily returns is +0.58 with S&P 500 (SPY), +0.62 with Nasdaq 100 (QQQ), +0.24 with Bitcoin (BTC) and +0.12 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
17 of 19 analysts rate it a buy or strong buy, 2 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $100.00 is 26.0% above the price.More buy ratings than three months ago ›
17 of 19 rate it a buy now, against 15 of 17 three months ago.
APH Wall Street View
12-month price targets
The price, $79.36, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 8, 2026 | Citigroup | Maintains | Buy |
| Oct 7, 2026 | UBS | Maintains | Buy |
| Oct 6, 2026 | Goldman Sachs | Maintains | Buy |
| Sep 23, 2026 | Bernstein | Initiates | Outperform |
| Sep 22, 2026 | BNP Paribas | Maintains | Outperform |
| Sep 9, 2026 | TD Cowen | Maintains | Hold |
As of October 17, 2026, 19 Wall Street analysts cover APH: 17 rate it a buy or strong buy, 2 a hold and 0 a sell or strong sell. Their 12-month price targets range from $85.00 to $116.00, with a median of $100.00, 26.0% above the price of $79.36.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
APH trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from APH's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much APH tends to move, against the market and on its own.
The long record
APH's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 2.21% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 36.4%, from January 2020 to March 2020, regained by August 2020.Most 1-year holds ended higher ›
91% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $139,667, against $42,058 in the S&P 500 (SPY).
APH Drawdowns & Recovery
As of October 17, 2026, APH's worst peak-to-trough fall over the last 10 years with dividends reinvested was -36.4% (January 2020 to March 2020); it regained that peak by August 2020, 5 months after the low, and 91% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into APH in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: APH beat the S&P 500 over this period: $139,667 against $42,058.
A $10,000 investment in APH in October 2016 would be worth about $139,667 today with dividends reinvested, compared with about $42,058 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to APH, and which have not.
Strongest month, November: an average of +6.06%, up in 10 of 10 years.
Weakest month, March: an average of -1.05%, up in 7 of 10 years.
This month, October: has averaged +3.22%, up in 7 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, APH's strongest calendar month has been November (average +6.06%, up in 10 of 10 years) and its weakest March (average -1.05%, up in 7 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in APH, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in APH today could grow to about $28,401 by 2036 in the base case, with a 90th-percentile outcome near $91,707 and a 10th-percentile outcome around $8,796. The simulation models price only; at today's 0.63% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
APH Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $120 for APH by 2030 in the base case, from $79.36 today (1.5x over 4 years). The 10th-percentile path ends near $57.41. These are outcomes of a Monte Carlo simulation run on APH's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $60.81 | $88.09 | $128 | |
| 2028 | $57.89 | $97.78 | $165 | |
| 2029 | $57.12 | $109 | $206 | |
| 2030 | $57.41 | $120 | $253 | |
| 2031 | $58.39 | $134 | $306 |
Method: a lognormal simulation of APH's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
APH insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $1.3M on the open market and sold $921.4M.
As of October 17, 2026, APH insiders reported 37 open-market sales worth $921.4M and 1 open-market purchase worth $1.3M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 6, 2026 | Craig A Lampo
Chief Financial Officer
|
Grant | 54.5K | - |
| Aug 5, 2026 | David M Silverman
Officer
|
Sell | 120.0K | $20.9M |
| Aug 5, 2026 | David M Silverman
Officer
|
Option | 120.0K | $2.6M |
| Aug 4, 2026 | Craig A Lampo
Chief Financial Officer
|
Sell | 193.2K | $32.3M |
| Aug 4, 2026 | Craig A Lampo
Chief Financial Officer
|
Option | 193.2K | $4.3M |
| Aug 3, 2026 | Lance E D'Amico
General Counsel
|
Sell | 100.0K | $16.2M |
| Aug 3, 2026 | Lance E D'Amico
General Counsel
|
Option | 100.0K | $2.2M |
| Jul 31, 2026 | Richard Adam Norwitt
Chief Executive Officer
|
Sell | 686.1K | $111.0M |
| Jul 31, 2026 | Richard Adam Norwitt
Chief Executive Officer
|
Option | 686.1K | $15.3M |
| May 22, 2026 | Nancy A. Altobello
Director
|
Grant | 1.6K | - |
| May 22, 2026 | David P Falck
Director
|
Grant | 1.6K | - |
| May 22, 2026 | Robert A Livingston
Director
|
Grant | 1.6K | - |
| May 5, 2026 | Richard Adam Norwitt
Chief Executive Officer
|
Sell | 130.8K | $18.7M |
| May 5, 2026 | Richard Adam Norwitt
Chief Executive Officer
|
Option | 130.8K | $2.9M |
| Feb 18, 2026 | Craig A Lampo
Chief Financial Officer
|
Sell | 100.0K | $15.0M |
| Feb 18, 2026 | Lance E D'Amico
General Counsel
|
Sell | 50.0K | $7.5M |
| Feb 18, 2026 | Lance E D'Amico
General Counsel
|
Option | 50.0K | $1.1M |
| Feb 18, 2026 | Craig A Lampo
Chief Financial Officer
|
Option | 100.0K | $2.2M |
| Feb 12, 2026 | Richard Adam Norwitt
Chief Executive Officer
|
Sell | 608.3K | $89.6M |
| Feb 12, 2026 | Richard Adam Norwitt
Chief Executive Officer
|
Option | 608.3K | $13.6M |
| Feb 5, 2026 | Robert A Livingston
Director
|
Buy | 10.0K | $1.3M |
| Feb 4, 2026 | Michael R Ivas
Officer
|
Option | 25.0K | $559.3K |
| Feb 4, 2026 | Michael R Ivas
Officer
|
Grant | 25.0K | - |
| Jan 8, 2026 | Sanjiv Lamba
Director
|
Grant | 548 | $74.7K |
| Dec 10, 2025 | Martin H Loeffler
Director
|
Grant | 3.2K | - |
| Dec 9, 2025 | Richard Adam Norwitt
Chief Executive Officer
|
Grant | 75.0K | - |
| Dec 3, 2025 | Craig A Lampo
Chief Financial Officer
|
Grant | 70.0K | - |
| Dec 2, 2025 | Peter John Straub
Officer
|
Sell | 132.0K | $18.7M |
| Dec 2, 2025 | William J Doherty
Officer
|
Sell | 80.0K | $11.4M |
| Dec 2, 2025 | William J Doherty
Officer
|
Option | 80.0K | $2.7M |
| Dec 2, 2025 | Peter John Straub
Officer
|
Option | 132.0K | $3.0M |
| Nov 26, 2025 | Craig A Lampo
Chief Financial Officer
|
Grant | 40.0K | - |
| Nov 11, 2025 | Craig A Lampo
Chief Financial Officer
|
Sell | 298.1K | $42.7M |
| Nov 11, 2025 | Craig A Lampo
Chief Financial Officer
|
Option | 340.1K | $7.5M |
| Nov 5, 2025 | Michael R Ivas
Officer
|
Sell | 120.0K | $16.8M |
| Nov 5, 2025 | Michael R Ivas
Officer
|
Option | 120.0K | $2.6M |
| Nov 3, 2025 | David M Silverman
Officer
|
Sell | 120.0K | $16.9M |
| Nov 3, 2025 | David M Silverman
Officer
|
Option | 120.0K | $2.6M |
| Oct 31, 2025 | Michael R Ivas
Officer
|
Sell | 120.0K | $17.0M |
| Oct 31, 2025 | Michael R Ivas
Officer
|
Option | 120.0K | $2.6M |
| Oct 29, 2025 | Lance E D'Amico
General Counsel
|
Sell | 120.0K | $16.8M |
| Oct 29, 2025 | William J Doherty
Officer
|
Sell | 80.0K | $11.3M |
| Oct 29, 2025 | Lance E D'Amico
General Counsel
|
Option | 120.0K | $2.7M |
| Oct 29, 2025 | William J Doherty
Officer
|
Option | 80.0K | $2.7M |
| Oct 28, 2025 | Richard Adam Norwitt
Chief Executive Officer
|
Option | 75.0K | $1.7M |
| Oct 28, 2025 | Richard Adam Norwitt
Chief Executive Officer
|
Grant | 75.0K | - |
| Oct 24, 2025 | Luc Walter
Officer
|
Sell | 365.1K | $49.2M |
| Oct 24, 2025 | Luc Walter
Officer
|
Grant | 80.0K | - |
| Oct 24, 2025 | Luc Walter
Officer
|
Option | 365.1K | $13.7M |
| Sep 8, 2025 | Peter J. Straub
Officer
|
Sell | 88.0K | $9.7M |
| Sep 8, 2025 | Peter J. Straub
Officer
|
Option | 88.0K | $2.0M |
| Aug 29, 2025 | Luc Walter
Officer
|
Grant | 18.0K | - |
| Aug 25, 2025 | David M Silverman
Officer
|
Sell | 100.0K | $11.0M |
| Aug 25, 2025 | Craig A Lampo
Chief Financial Officer
|
Sell | 40.1K | $4.4M |
| Aug 25, 2025 | Craig A Lampo
Chief Financial Officer
|
Option | 40.1K | $881.7K |
| Aug 25, 2025 | David M Silverman
Officer
|
Option | 100.0K | $1.8M |
| Aug 22, 2025 | Craig A Lampo
Chief Financial Officer
|
Sell | 199.8K | $22.1M |
| Aug 22, 2025 | Craig A Lampo
Chief Financial Officer
|
Option | 199.8K | $4.4M |
| Aug 18, 2025 | Lance E D'Amico
General Counsel
|
Sell | 100.0K | $11.1M |
| Aug 18, 2025 | Lance E D'Amico
General Counsel
|
Option | 100.0K | $2.3M |
| Aug 11, 2025 | William J Doherty
Officer
|
Sell | 226.0K | $24.8M |
| Aug 11, 2025 | William J Doherty
Officer
|
Option | 226.0K | $5.1M |
| Aug 8, 2025 | Michael R Ivas
Officer
|
Sell | 50.0K | $5.5M |
| Aug 8, 2025 | Michael R Ivas
Officer
|
Option | 50.0K | $911.5K |
| Jun 3, 2025 | Luc Walter
President
|
Sell | 286.0K | $26.1M |
| Jun 3, 2025 | Luc Walter
President
|
Option | 286.0K | $6.5M |
| May 30, 2025 | William J Doherty
Officer
|
Sell | 160.0K | $14.3M |
| May 30, 2025 | David M Silverman
Officer
|
Sell | 100.0K | $8.9M |
| May 30, 2025 | William J Doherty
Officer
|
Option | 160.0K | $3.6M |
| May 29, 2025 | Michael R Ivas
Officer
|
Sell | 40.0K | $3.6M |
| May 29, 2025 | Michael R Ivas
Officer
|
Option | 40.0K | $729.2K |
| May 16, 2025 | Prahlad R Singh
Director
|
Grant | 2.4K | - |
| May 13, 2025 | Lance E D'Amico
General Counsel
|
Sell | 100.0K | $8.6M |
| May 13, 2025 | Lance E D'Amico
General Counsel
|
Option | 125.0K | $2.8M |
| May 2, 2025 | William J Doherty
Officer
|
Sell | 126.0K | $10.1M |
| May 2, 2025 | David M Silverman
Officer
|
Sell | 87.5K | $7.0M |
| May 2, 2025 | William J Doherty
Officer
|
Option | 126.0K | $2.8M |
| Apr 25, 2025 | Richard Adam Norwitt
Chief Executive Officer
|
Sell | 2.0M | $151.5M |
| Apr 25, 2025 | Craig A Lampo
Chief Financial Officer
|
Sell | 400.0K | $30.4M |
| Apr 25, 2025 | Luc Walter
Officer
|
Sell | 390.0K | $29.6M |
| Apr 25, 2025 | Lance E D'Amico
General Counsel
|
Sell | 205.0K | $15.6M |
| Apr 25, 2025 | David M Silverman
Officer
|
Sell | 100.0K | $7.6M |
| Apr 25, 2025 | William J Doherty
Officer
|
Sell | 100.0K | $7.5M |
| Apr 25, 2025 | Lance E D'Amico
General Counsel
|
Option | 205.0K | $4.6M |
| Apr 25, 2025 | William J Doherty
Officer
|
Option | 100.0K | $2.2M |
| Apr 25, 2025 | Richard Adam Norwitt
Chief Executive Officer
|
Option | 2.0M | $44.0M |
| Apr 25, 2025 | Luc Walter
Officer
|
Option | 440.0K | $9.9M |
| Apr 25, 2025 | Luc Walter
Officer
|
Grant | 46.0K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.